Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bioequivalence Clear all
Completed Phase 1 Interventional

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

NCT05148689
View directory record Official record
Conditions
Bioequivalence
Interventions
Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg

NCT00650325
View directory record Official record
Conditions
Healthy
Interventions
Sertraline Hydrochloride Tablets 100 mg, Zoloft® Tablets 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Nicotine Lozenge Bioequivalence Study

NCT01536704
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine (2 mg), Nicotine (4 mg)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

NCT04421885
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference, Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)

NCT00978055
View directory record Official record
Conditions
Healthy
Interventions
1: Liothyronine Sodium Tablets, 2: Cytomel® Tablets
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations

NCT01039584
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
Butoconazole Nitrate Vaginal Cream, Placebo, Gynazole 1 vaginal cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Jul 23, 2026, 10:08 AM EDT
Terminated Phase 3 Interventional

WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients

NCT00275314
View directory record Official record
Conditions
Kidney Transplant
Interventions
Valganciclovir
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 68 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

NCT04856293
View directory record Official record
Conditions
Healthy Participants
Interventions
Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects

NCT02821338
View directory record Official record
Conditions
Healthy
Interventions
Lamotrigine Extended Release
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

NCT00648349
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Delayed-Release Tablets 20 mg, Aciphex® Delayed-Release Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions

NCT00865943
View directory record Official record
Conditions
Healthy
Interventions
Citalopram HBr eq. 10 mg tablets, single dose, CELEXATM 10 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions

NCT00934180
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron, Zofran®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.

NCT00609596
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
GI198745
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

NCT06440980
View directory record Official record
Conditions
Healthy, Obese, Overweight, Obesity
Interventions
Orforglipron
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Anaheim, California • Los Alamitos, California • Daytona Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

NCT05069896
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab Prefilled Syringe, Mirikizumab Autoinjector
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Finasteride 5 mg Tablets, Non-fasting

NCT00835796
View directory record Official record
Conditions
Healthy
Interventions
Finasteride 5 mg tablets, PROSCAR® 5mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg

NCT00648362
View directory record Official record
Conditions
Healthy
Interventions
Glimepiride Tablets 1 mg, Amaryl® Tablets 1 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02071368
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/500, CANA/MET XR FDC, Formulation 2, 150 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations

NCT00612768
View directory record Official record
Conditions
Dermatitis, Contact
Interventions
TRUE Test allergens Fragrance Mix and Thimerosol
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Little Rock, Arkansas • Shawnee Mission, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

NCT04561115
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Gamunex-C, IVIG-PEG
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • North Palm Beach, Florida • South Bend, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

NCT05181215
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg
Drug
Lead sponsor
Banner Life Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study Metformin Hydrochloride ER Tablets 750 mg and Glucophage XR 750 mg

NCT00649350
View directory record Official record
Conditions
Healthy
Interventions
Metformin Hydrochloride ER Tablets 750 mg, Glucophage XR 750 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

NCT02498418
View directory record Official record
Conditions
Diarrhea
Interventions
Rifaximin, Xifaxan®, Placebo Tablet
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 3 Interventional

A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte

NCT00198523
View directory record Official record
Conditions
Eye Infections, Postoperative Complications
Interventions
Prednisolone and Tobramycin, Prednisolone
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
Great Bend, Kansas • Boston, Massachusetts • Saint Joseph, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Jul 23, 2026, 10:08 AM EDT